ABCA4-related retinopathy

This early-phase trial tests a new gene therapy called VG801 for Stargardt disease, a genetic condition that causes vision loss. Fifteen people aged 6 and older will receive a single injection under the retina. The main goal is to check safety, but researchers will also measure a…

This early-stage trial tests a gene therapy called ZVS106e for Stargardt disease, a genetic condition that causes vision loss. Nine participants will receive a single injection of the drug under their retina. The main goal is to check safety over 52 weeks, not yet to prove it wor…

This early study tests a new gene therapy called ACDN-01 for people with Stargardt disease, a genetic condition that leads to progressive vision loss. The therapy is given as a one-time injection under the retina. The main goals are to check safety and find the right dose, with a…

This prescreening study aims to identify up to 50 people with ABCA4-related retinopathy, including Stargardt disease, for possible participation in future ACDN-01 clinical trials. Participants will undergo genetic testing and various eye exams to confirm their condition. This is …